BioMarin Pharma (BMRN) Tops Q4 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.82 +1.05%
EPS Growth %: -34.0%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
CRMT, FOMI, FLES, More
EPS Growth %: -34.0%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.00, which may not compare to the analyst estimate of ($0.06). Revenue for the quarter came in at $537.5 million versus the consensus estimate of $537.62 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.61. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 billion, versus the consensus of $2.58 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- AeroVironment (AVAV) Tops Q4 EPS by 36c
- Columbus McKinnon names John Linker as CFO, reaffirms FY2027 guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
